Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Out of Compliance With Nasdaq Listing Rules

NEW YORK (GenomeWeb) — Australian molecular diagnostics firm Genetic Technologies said today that it has received a notice from the Nasdaq Stock Market that it is no longer in compliance with the stock exchange's listing requirements.

According to Genetic Technologies, the Nasdaq said that the company's reported shareholders' equity is less than the required minimum of $2.5 million as of the end of 2018, and that it does not meet the alternatives of market value of listed securities or net income from continuing operations.

Genetic Technologies said it has 45 days to submit a plan, which it intends to do, to the Nasdaq as to how it will regain compliance. If the plan is accepted, Genetic Technologies will be eligible for an 180-day extension to meet the listing requirements.

Genetic Technologies noted that the matter does not affect its listing on the Australian Securities Exchange.

During early Friday morning trading on the Nasdaq, shares of Genetic Technologies were up less than 1 percent at $.7607.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.